• Explore /
  • Poster
  • / A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer.

A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer.

Abstract Poster

Authors

null

Susana N. Banerjee

The Royal Marsden and The Institute of Cancer Research, London, United Kingdom

Susana N. Banerjee , Alvaro Ingles Russo , Andrea Biondo , Ionut-Gabriel Funingana , Martin Little , Toby Prout , Mona Parmar , Bora Gurel , Ruth Riisnaes , Ben Jenkins , Emma Hall , Ed Ainscow , Stuart McIntosh , Nina Tunariu , Anna Rachel Minchom , Juanita Suzanne Lopez , Johann S. De Bono , Natalie Cook , Bristi Basu , Udai Banerji

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02360345

Citation

J Clin Oncol 38: 2020 (suppl; abstr 6043)

DOI

10.1200/JCO.2020.38.15_suppl.6043

Abstract #

6043

Poster Bd #

214

Abstract Disclosures

Similar Posters

First Author: Xiao-Li Wei

First Author: Funda Meric-Bernstam

First Author: Charlie Gourley

First Author: J. Andrew Livingston